Actively Recruiting
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
Led by Centre Hospitalier Intercommunal Aix-Pertuis · Updated on 2024-09-23
40
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit. The main questions it aims to answer are: * evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.
CONDITIONS
Official Title
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Patient admitted in the Intensive Care Unit of the CHIAP
- Patient under mechanical ventilation
- Patient with infectious pneumonia
- Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
- Patient beneficiary of French social security, whatever the regime
You will not qualify if you...
- Patient under 18 years old
- Patient with severe neutropenia (neutrophils < 0.5 G/L)
- Patient under immunosuppressive treatment
- Use of corticosteroids (intravenous or oral) prior to ICU admission
- Use of therapeutic antibodies
- Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
- End of chemotherapy 6 months prior to inclusion
- Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)
- Patients with a decision to limit or discontinue active therapies, at the time of inclusion
- Patients with an estimated ICU stay of less than 48 hours
- Participation in an interventional study
- Patient deprived of their liberty
- Patient under tutorship or curatorship
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Intercommunal Aix-Pertuis
Aix-en-Provence, France, 13100
Actively Recruiting
Research Team
L
Laurent LEFEBVRE, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here